The Cooper Companies, Inc. (NASDAQ:COO) Shares Sold by Axa S.A.

AXA S.A. cut its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 60.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 66,693 shares of the medical device company's stock after selling 100,801 shares during the quarter. AXA S.A.'s holdings in Cooper Companies were worth $6,131,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in COO. T. Rowe Price Investment Management Inc. grew its holdings in shares of Cooper Companies by 2.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 7,678,965 shares of the medical device company's stock worth $705,928,000 after purchasing an additional 155,233 shares during the period. JPMorgan Chase & Co. grew its stake in Cooper Companies by 1.5% during the fourth quarter. JPMorgan Chase & Co. now owns 5,004,523 shares of the medical device company's stock worth $460,066,000 after buying an additional 74,501 shares during the period. Geode Capital Management LLC increased its position in shares of Cooper Companies by 2.3% in the fourth quarter. Geode Capital Management LLC now owns 4,906,463 shares of the medical device company's stock worth $449,907,000 after acquiring an additional 109,907 shares in the last quarter. Victory Capital Management Inc. raised its stake in shares of Cooper Companies by 14.6% in the 4th quarter. Victory Capital Management Inc. now owns 4,525,018 shares of the medical device company's stock valued at $415,985,000 after acquiring an additional 574,899 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Cooper Companies by 517.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,529,477 shares of the medical device company's stock valued at $324,466,000 after acquiring an additional 2,957,421 shares in the last quarter. 24.39% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on COO shares. Citigroup decreased their target price on Cooper Companies from $115.00 to $110.00 and set a "buy" rating for the company in a research report on Friday, March 7th. BNP Paribas upgraded shares of Cooper Companies to a "hold" rating in a research note on Thursday, March 13th. Robert W. Baird decreased their target price on shares of Cooper Companies from $117.00 to $107.00 and set an "outperform" rating for the company in a research note on Friday, March 7th. Piper Sandler reaffirmed an "overweight" rating and set a $115.00 price target (down previously from $120.00) on shares of Cooper Companies in a research note on Friday, March 7th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Cooper Companies from $120.00 to $110.00 and set an "overweight" rating for the company in a research report on Friday, March 7th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $110.25.

Cooper Companies Stock Performance

Shares of COO stock traded down $0.65 on Friday, hitting $82.27. 1,265,544 shares of the stock traded hands, compared to its average volume of 1,447,855. The company's fifty day moving average is $80.54 and its 200 day moving average is $90.93. The Cooper Companies, Inc. has a 1-year low of $69.81 and a 1-year high of $112.38. The company has a market capitalization of $16.45 billion, a PE ratio of 42.19, a PEG ratio of 2.25 and a beta of 1.08. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12.

Cooper Companies (NASDAQ:COO - Get Free Report) last posted its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.92. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The company had revenue of $964.70 million for the quarter, compared to the consensus estimate of $981.25 million. On average, equities research analysts predict that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.